Jane Street’s PDS Biotechnology PDSB Stock Holding History

Jane Street’s Portfolio PDSB Stock Details PDSB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-23,800	Closed	-$120K	–	9184
2023 Q2	$120K	Buy	+23,800	New	+$156K	﹤0.01%	7928

Other funds holding PDSB

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

IWA

Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jane Street's PDSB Position: Q4 2025 in Review

Jane Street sold out of PDS Biotechnology (PDSB) in Q4 2025, closing a stake of 36,581 shares — an estimated $36.9K sold.

Jane Street first reported a position in PDSB in Q2 2018 and held it in 14 quarters. The position peaked at $762K in Q1 2023. 44 funds tracked by Wall St. Rank hold PDSB as of Q4 2025.

Jane Street reported no remaining PDS Biotechnology position as of Q4 2025 after selling out during the quarter.
Jane Street sold 36,581 PDS Biotechnology shares in Q4 2025, an estimated $36.9K.
Jane Street first reported a position in PDS Biotechnology in Q2 2018 and held it in 14 quarters.
Jane Street's PDS Biotechnology position peaked at $762K in Q1 2023.
44 funds tracked by Wall St. Rank held PDS Biotechnology as of Q4 2025.

Based on Jane Street's 13F filing for Q4 2025, filed 12 Feb 2026.